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Patient # Age/sex Involvement Pretreatment Status at alloSCT Conditioning Donor Outcome
1 64/m Skin ALL-like, HD-Mtx CR2 Flu-Bu-Cy-ATG MMUD 8/10 Chronic GVHD, alive in CR, 441 mo
2 67/m Skin, BM ALL-like, Gemcitabine Refractory Flu-Bu-Cy-ATG MMUD 9/10 Dead (REL 71 mo)
3 69/m Skin, BM AML-like Refractory Flu-Treosulfan-ATG MUD 10/10 Alive in CR 71 mo
4 55/f Skin ALL-like CR1 Flu-Bu-Cy-ATG MUD 10/10 Alive in CR 51 mo
Poster Session I S233Six consecutive patients with BPDC have been treated at our insti-
tution between 2004 and 2008. All patients responded to acute leu-
kemia-like induction therapy. Whereas two patients were ineligible
for alloSCT due to comorbidity and experienced rapid relapse, 4 pa-
tients proceeded to RIC alloSCT as part of first-line (n5 1) or sal-
vage treatment (n5 3) (Table). Median age was 66 (55-69) years.
Two patients had active disease at the time of alloSCT. Condition-
ing was based on submyeloablative doses of busulfan or treosulfan
with fludarabine and ATG, followed by transplantation of unmanip-
ulated peripheral blood stem cell grafts obtained from matched or
mismatched unrelated donors. Three patients live progression-free
44, 7 and 5months post alloSCT, one patient relapsed 7months after
SCT and died soon thereafter.
We conclude that RIC SCT from unrelated donors is feasible in
elderly patients with BPDC and might provide curative potential
in this otherwise incurable disease. Prospective analyses of RIC al-
loSCT in BPDC are warranted.202
OUTCOME OF ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEU-
KEMIA (EALL) WITH CHEMOTHERAPY: THE VANCOUVER EXPERIENCE
Tantiworawit, A., Barnett, M.J., Forrest, D.L., Hogge, D.E.,
Nantel, S.H., Narayanan, S., Nevill, T.J., Power, M.M.,
Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J.,
Toze, C.L., Abou Mourad, Y.R. University of British Columbia, Vancou-
ver, BC, Canada
Introduction: Age remains probably the most important prognos-
tic factor in acute lymphoblastic leukemia (ALL). Adults with ALL
have poor outcome with chemotherapy when compared to chil-
dren; as age increases overall survival (OS) continuously declines.
Elderly ALL (EALL) patients (pts) have the worst outcome with
chemotherapy. Despite good initial response to induction chemo-
therapy, relapse rate (RR) is high and most pts will succumb to
their disease. Few studies have addressed the outcome of EALL
with chemotherapy.
Patients and Methods: Retrospective analysis of 32 EALL pts
treated with chemotherapy at the L/BMT program of BC, Canada
between 1989-2008. EALL was defined by age $60 years. Cytoge-
netics was available on 28(87.5%) pts. All pts received a consistent in-
duction/consolidation and maintenance chemotherapy as per our
modified ALL89-01 protocol. Complete remission (CR), Event
free survival (EFS) and OS were analyzed.
Results:Betwen1989-2008, 32 pts (8.7% of adult ALL) were EALL,
median age 66.0(60.1-76.1) years, 50% males. Median wbc count
was 7.4(0.8-43) x109/L. 7/32(28%) were Ph+. Only one pt had
CNS involvement. All pts received a consistent induction with dau-
norubicin, vincristine and prednisone. 27/32(84.4%) achieved CR.
18/27(66.7%) of pts. who achieved CR received phase II induction
consisting of cyclophosphamide, cytarabine, and mercaptopurine.
Consolidation chemotherapy was given in 17/27 (62.9%), in 15/
17(88.2%) consisted of 1-2 cycle of cytarabine and tenoposide. 6
pts also received modified intensification with vincristine, daunoru-
bicin, cyclophosphamide. 4 pts received tyrosine kinase inhibitor
(TKI) with consolidation. 2 pts received other chemotherapy. Main-
tenance with methotrexate and mercaptopurine were given in 20 pts
which include 4 pts who did not receive consolidation. 23/27(85.2%)
pts who achieved CR had relapse. Median time to relapse from diag-
nosis is 240(112-1317) days. Median EFS and OS are 313(0-1317)
and 489(38-1770) days, respectively. Cause of death was disease pro-
gression in 25/27 (92.6%). 6/7(85%) of Ph+ pts received combina-tion chemotherapy with TKI. 3-year OS for the whole group was
26%, 36% for Ph+ pts and 23% for Ph- ALL.
Conclusions: EALL have poor outcome with chemotherapy. De-
spite the excellent CR rate with chemotherapy (84.4%), RR remains
high (85.2%) and most patients (96.2%) die secondary to DP. In the
TKI’s era, EALL with Ph+ disease relatively fair better than Ph-
EALL.
3-year disease free survival and over all survival
All Patient Ph1 group Ph- group P valueNumber 32 7 25
3-year DFS 15% 0% 19% 0.20
3-year-OS 26% 36% 23% 0.81LYMPHOMA/MULTIPLE MYELOMA
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH
REDUCED-INTENSITY CONDITIONING IN PATIENTS WITH REFRACTORY
AND RELAPSING MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP
Shimoni, A.1, Hardan, I.1, Ayuk, F.2, Schilling, G.2, Atanackovic, D.2,
Zeller, W.2, Shem-Tov, N.1, Rand, A.1, Yerushalmi, R.1, Zander, A.2,
Kro¨ger, N.2, Nagler, A.1 1 Chaim Sheba Medical Center, Tel-Hashomer,
Israel; 2 University Hospital Hamburg, Hamburg, Germany
Allogeneic SCTwithmyeloablative conditioning is potentially cu-
rative therapy for multiple myeloma (MM), but is associated with ex-
cessively high rates of non-relapse mortality (NRM). Reduced-
intensity conditioning (RIC) allows reduction of NRM but relapse
rate is increased. The role and timing of allogeneic SCT during
the disease course are controversial. There is only limited data on
the long-term outcome of RIC in the relapsing/refractory setting.
We retrospective analyzed SCT outcomes in 50 patients (pts) given
RIC for relapsing/refractory MM, between the years 2000-2004,
from related (n5 27) or unrelated (n5 23) donors. The median
age was 53 years (32-64). This was a relatively heavily pretreated
group, amedian of 3 years from diagnosis (0.5-14 years). Forty-seven
pts failed one (n5 31) or two (n5 16) prior autologous SCT. Thirty
pts were in PR (n5 26) or CR (n5 4) at the time of SCT and 20 pts
had stable or progressive disease. RIC consisted of fludarabine and
melphalan (100-140 mg/m2). Disease response was assessed at day
+100; 23 pts achieved CR; 17 PR, 7 died and 3 have already pro-
gressed by day +100. With a median follow-up of 6.4 years (range,
5-7.9 years), 16 pts are alive and 34 have died; 13 had NRM (cumu-
lative incidence 26%) and 21 died of relapse. The median survival is
2.3 years and the estimated 7-year overall and progression-free sur-
vival (PFS) rates were 34% (95 C.I. 21-47%) and 26% (95 C.I. 14-
38%), respectively. The PFS curve showed an apparent plateau after
3 years, with no later relapses, suggesting a potential cure. In multi-
variate analysis, adverse prognostic factors for survival included SCT
not in remission, long duration of disease and SCT from a female do-
nor to a male recipient. Related and unrelated donor SCT had a sim-
ilar outcome. The 7 year PFS in 19 pts with none of these adverse
factors was 47%. Chronic GVHD and achievement of CR after
SCTwere associated with improved outcome. In conclusion, alloge-
neic SCT can result in long-term PFS in a subset of MM pts failing
prior therapy and should be considered early after failure and prefer-
ably after achieving a response with salvage therapy. The treatment
goal is to achieve a CR as this is associated with better outcome.
S234 Poster Session IRelapsing disease is still the major cause of treatment failure. Addi-
tional strategies, such as maintenance therapy with novel agents or
judicious use of donor lymphocyte infusions merit further investiga-
tion for converting PR to CR and reducing relapse risk.204
THE GRAFT-VERSUS-MYELOMA EFFECT USING NON-MYELOABLATIVE
OR REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT)
Ringden, O.1, Barrett, J.2, Shrestha, S.3, Tunes, da Silva G.4, Zhang, M.-
J.3, Dispenzieri, A.5, Remberger, M.1, Kamble, R.6, Freytes, C.7,
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ter, MN; 6 Baylor College of Medicine, Houston, TX; 7 University of Texas,
San Antonio, TX; 8 UCLA Medical Center, Los Angeles, CA; 9 Royal
Prince Alfred Hospital, Sydney, Australia; 10 Princess Margaret Hospital,
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Following myeloablative conditioning due to high treatment-re-
lated mortality (TRM), some studies have shown an inferior out-
come using allogeneic HSCT compared to autologous transplant.
More recently, non-myeloablative (NMA) and reduced intensity
conditioning (RIC) for allogeneic HSCT was introduced. A prereq-
uisite for this approach is a significant graft-versus-myeloma effect,
which has not clearly been demonstrated. Between 1997 and 2005,
177 patients were reported to the CIBMTR following NMA
(n5 120) or RIC (n5 57) and an allogeneic HSCT from an HLA-
identical sibling donor. Median age was 50 years (range 24-69).
Planned tandem autologous transplant followed by allogeneic
HSCT was given to 105 of these patients. Most patients were given
peripheral blood stem cells (98%). Outcomes, with a median follow-
up of 55 months (range 3-98) and 25 months (range 3-76) respec-
tively for allogeneic HSCT and autologous transplant followed by
allogeneic HSCT, see Table below.
The following variables were significant in univariate outcomes
analyses and were therefore used in the multivariate modelling:
age, sex, performance status, IgG vs. non IgG myeloma, disease sta-
tus and chemosensitivity, prior lines of chemotherapy, donor-recip-
ient sex match, NMA vs. RIC, year of transplant and GVHD as the
time dependent covariate. The only factor on multivariate analysis
that increased the risk of TRM was acute GVHD (RR 2.38,
p5 0.018). Only chronic GVHD decreased the probability of re-
lapse on multivariate (RR 0.43, p5 0.012), but this effect was not
seen in patients with IgGmyeloma (n5 97, RR 0.7, p5 0.3) in com-
parison to all other types of myeloma (n5 80, RR 0.11, p5 0.004).
Improved PFS was associated with autologous + allogeneic HSCT
(RR 3.6, p5 0.001) and absence of acute GVHD (p5 0.001), but
not chronicGVHD (RR 0.9, p5 0.7). In conclusion, patients receiv-
ing allogeneic HCT for myeloma, chronic GVHD decreased the
probability of relapse, but only in patients with non-IgG myeloma.
PFS was improved in patients receiving autologous + allogeneic
HCT and was decreased in those with acute GVHD.
Outcomes Allo only Auto1AlloNumber of patients 72 105
Acute GVHD at 100 days, grades (1-4) 47 (37-60)% 37 (28-46)%
Chronic GVHD at 3 years 55 (43-67)% 58 (43-72)%
Treatment Related Mortality (TRM) at
3 years
27 (17-38)% 16 (10-25)%Relapse at 3 years 48 (36-60)% 41 (29-54)%
Progression-free survival (PFS) at 3
years
25 (15-37)% 42 (20-43)%Overall Survival at 3 years 45 (33-58)% 64 (53-75)%205
PHENOTYPIC ANALYSIS OF MULTIPLE MYELOMA CELL PROGENITORS
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The lack of specific molecules to define the multiple myeloma
(MM) malignant cells responsible for disease development and re-
lapse has hampered the evaluation of minimal residual disease
(MRD) in MM. PC development compromises an array of sub-
populations with distinctive phenotypes. Syndecan (CD138) is ex-
pressed in plasma cells (PC) and studies using CD138+ selected
cells may be problematic since earlier progenitors may be ex-
cluded. To define myeloma bone marrow (BM) progenitor phe-
notype we developed a multicolor flow cytometry assay to
study them. We have identified a CD138- subset that co-express
CD19+, CD27+ and identical kappa or lambda light chain re-
striction as the abnormal plasma cells, as previously shown by
others. Further characterization has shown that this subset co-ex-
presses the c-Kit (CD117) (20%) and Notch-1 receptors (90%) as
the hematopoietic stem cells (HSC) CD34+ counterpart. A small
percentage of this BM cells show aldehyde dehydrogenase
(ALDH) activity. Flow sorting of CD138- was feasible with
99% purity. Isolated populations were grown in methylcellulose
with 5% PHA-leukocyte conditioned medium. CD138+ cells
did not exhibit colony formation, and neither did the CD138-/
CD38+/CD19-/CD34- cells. Instead, CD138-/CD38+/CD19+/
CD34- cells were able to grow cell colonies (.100 cells) al-
though their efficiency was low (1 in 15,000). CD34+ cells
(HSC) also were able to grow cell colonies but with a significant
lesser efficiency compared to SCF, IL-3 and GM-CSF cytokine
stimulation. Cells harvested at day 14 from CD34+ and
CD138-/CD38+/CD19+/CD34- generated colonies showed
a lympho-plasmacytoid appearance. We showed that only
CD138-/CD38+/CD19+/CD34- cells, but not CD34 +HSC, dif-
ferentiated into a more mature syndecan (CD138+) expressing
cell as determined by flow cytometry. Isolated CD138-/CD38+/
CD19+/CD34- cells shown to be relatively bortezomib-resistant
when compared to CD138+ plasma cells. The lacking expression
of mature PC markers in this MM sub-population makes us hy-
pothesize that they represent a progenitor B cells that differenti-
ate into the malignant PC. Surrogate assays for stem cell activity
(long term culture-initiating cell (LTC-IC), cobblestone-area
forming cells (CAFC) and xenotransplant models should deter-
mine cancer stem cell activity of these cells. Research studies of
these CD138- MM putative progenitor cells may lead to develop
novel treatments to target MM subpopulations that may consti-
tute the MRD reservoir.206
EFFICACY AND SAFETY OF CHEMOMOBLIZATION WITH VP-16 AND G-
CSF IN PATIENTS (PTS) UNDERGOING AUTOLOGOUS STEM CELL TRANS-
PLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM)
Wood, W.A., Whitley, J.S., Moore, D.T., Sharf, A., Irons, R., Rao, K.V.,
Serody, J.S., Gabriel, D.A., Coghill, J.M., Shea, T.C. University of North
Carolina at Chapel Hill, NC
Introduction: Although the number of ASCTs performed for
MM continues to increase, the optimal mobilization strategy re-
mains unclear. Additionally, concern has arisen about the impact
of age and prior lenalidomide exposure on mobilization efficacy.
High dose etoposide has been previously shown to have antitumor
activity and efficacy in progenitor cell mobilization, and has a fa-
vorable safety profile when cytokine is also given (Gianni et al.,
JCO 1992). Here, we report on the efficacy and safety of mid-
dose etoposide and G-CSF as a mobilization regimen for pts
with MM.
Methods: Between May 2004 and June 2009, 152 pts with MM un-
derwent ASCT following the use of VP-16 (375 mg/m2 on D#1 and
D#2) and G-CSF (5mcg/kg twice daily from D#3 through the final
day of collection) for mobilization. 65 pts were female, 87 were
male, and median age was 56 yrs (range 17-72). Collection was
